TriangleNCT02666950 · OUTCOME
Time to Progression, Defined as the Time From Registration to the Earliest Date of Documentation of Disease Progression
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- Full Range
- Time frame
- Up to 17 months
What was measured
Time to progression (TTP) is defined to be the length of time from study registration to a) date of disease progression as defined by section 11.0 of the protocol, or b) last follow-up. If a patient dies without documentation of disease progression, the patient will be considered to have had a tumor progression at the time of death unless there is sufficient documented evidence to conclude no progression occurred prior to death. Time to progression curves were compared via the log-rank test. Progression is defined as a \>25% increase in product of perpendicular diameters of contrast enhancement or mass or appearance of new lesions or unequivocal increase in size of contrast enhancement or increase in mass effect as agreed upon independently by primary physician and quality control physicians: appearance of new lesions compared to pretreatment MRI and/or CT scan.
Analysis population: Since only one patient was accrued on one arm, patient confidentiality prevents the reporting of results by arm.
Groups in this outcome
Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only)
Patients receive 20 mg cytarabine (AraC) SC twice daily and 200 mg WEE1 inhibitor (AZD1775) PO daily on days 1-5 and days 8-12 OR receive only 200 mg WEE inhibitor (AZD1775) PO daily on days 1-5, 8-12, 15-19, and 22-26.
| Group | Source count |
|---|---|
| Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only) | 3 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only) | 3.9 | Not reported | 3.8 | 6.9 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 3.8
- upper Limit
- 6.9
- value
- 3.9
- denoms
- counts
- group Id
- OG000
- value
- 3
- units
- Participants
- description
- Time to progression (TTP) is defined to be the length of time from study registration to a) date of disease progression as defined by section 11.0 of the protocol, or b) last follow-up. If a patient dies without documentation of disease progression, the patient will be considered to have had a tumor progression at the time of death unless there is sufficient documented evidence to conclude no progression occurred prior to death. Time to progression curves were compared via the log-rank test. Progression is defined as a \>25% increase in product of perpendicular diameters of contrast enhancement or mass or appearance of new lesions or unequivocal increase in size of contrast enhancement or increase in mass effect as agreed upon independently by primary physician and quality control physicians: appearance of new lesions compared to pretreatment MRI and/or CT scan.
- dispersion Type
- Full Range
- groups
- description
- Patients receive 20 mg cytarabine (AraC) SC twice daily and 200 mg WEE1 inhibitor (AZD1775) PO daily on days 1-5 and days 8-12 OR receive only 200 mg WEE inhibitor (AZD1775) PO daily on days 1-5, 8-12, 15-19, and 22-26.
- id
- OG000
- title
- Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only)
- param Type
- MEDIAN
- population Description
- Since only one patient was accrued on one arm, patient confidentiality prevents the reporting of results by arm.
- reporting Status
- POSTED
- time Frame
- Up to 17 months
- title
- Time to Progression, Defined as the Time From Registration to the Earliest Date of Documentation of Disease Progression
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice